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Aims: Risk scores are commonly used to identify high-risk patients eli-
gible for transcatheter aortic valve replacement (TAVR) and to predict
periprocedural mortality. EuroSCORE 2 has been recently assessed as a pre-
dictor of mortality for cardiac surgery but it has never been evaluated for
TAVR.
Methods and Results: Consecutive patients (n=250) in whom a bal-
loon-expandable Edwards prosthesis was implanted between 2006 and
2011 were included for analysis. Patient demographics were recorded in a
prospective database. Correlations and c-statistic were calculated for
logistic EuroSCORE, Society of Thoracic Surgeons (STS) score, and
EuroSCORE 2. The primary end point was 30-day mortality and occurred
in 7.6%. The mean logistic EuroSCORE was 22.6±12.8% and overesti-
mated mortality as compared to STS (7.3±4.1%) and EuroSCORE
2 (7.7±5.8%) scores. EuroSCORE 2, but not logistic EuroSCORE and STS
scores, was significantly higher in patients who died as compared to those
who survived (10.3±6.0% vs. 7.5±5.7%, p=0.04; 27.6±13.4% vs.
22.2±12.7%, p=0.07 and 9.5±6.7% vs. 7.1±3.8%, p=0.13, respectively).
The best linear correlation was observed between the Logistic Euro-
SCORE and EuroSCORE 2 (r=0.79, p<0.001). The area under the curve
was 0.66 (95% CI 0.52-0.79, p=0.02) for EuroSCORE 2, 0.63 (95% CI
0.51-0.76, p=0.06) for logistic EuroSCORE, and 0.58 (95% CI 0.43-0.73,
p=0.23) for STS score.
Conclusions: EuroSCORE 2 was superior to logistic EuroSCORE and
STS scores in predicting 30-day mortality after TAVR. However, Euro-
SCORE 2 had only moderate accuracy in predicting mortality after TAVR.
Further studies are warranted to confirm theses results in a larger popula-
tion.
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Contexte : Dans le RM, les Recommandations Internationales préconisent
la dilatation mitrale lorsqu’à l’écho-doppler cardiaque de stress le gradient
mitral moyen au pic de l’effort est supérieur à 15 mm Hg (grade C).
Objectif : Étude du gradient mitral moyen à l’écho-doppler cardiaque per
effort dans le RM avec une surface mitrale ≤2 cm².
Résultats : 300 malades ont été inclus. L’âge moyen était de 42,7 ± 1,3 ans, le
sex ratio de 0,23. Selon la surface mitrale (SM), 3 groupes ont été définis. G1 :
SM ≤ 1 cm² (n=72), G2 : 1 cm² < SM < 1,5 cm² (n=128) et G3 : SM ≥ 1,5 cm²
(n=100). La SM moyenne était égale à 0,8 ± 0.1 cm² (G1), 1,3 ± 0,1 cm² (G2) et
1,7 ± 0.1 cm² (G3) (p < 10-6). Au repos, du 1er au 3e groupe, la fréquence cardiaque
était respectivement égale à 71,5 ± 2,7, 76,3 ± 1,7, 73,6 ± 2,1, et le gradient mitral
moyen respectivement égal à 11,6 ± 0,8 mm Hg, 8,8 ± 0,5 mm Hg et
5,1 ± 0,3 mm Hg (p < 10-6). Au pic de l’effort, la fréquence cardiaque était de
152,3 ± 2,9 (G1), 150,7 ± 2,2 (G2), 148,7 ± 2,4 (G3) (p=0.20), et le gradient mitral
moyen égal à 39.2±2.1 mm Hg (G1), 31,5 ± 1,3 mm Hg (G2) et 22,8 ± ,0 mm Hg
(G3) (p < 10-6). Au maximum de l’effort, le gradient mitral moyen était supérieur
à 15 mm Hg chez 90 patients (90%) du groupe 3 malgré une SM ≥ 1,5 cm². Tous
les malades des groupes 2 et 1 ont augmenté leur gradient mitral moyen au-delà
de 15 mm Hg au pic de l’effort.
Conclusion: Au maximum de l’effort, la plupart de nos malades ont aug-
menté leur gradient mitral moyen au-delà de 15 mm Hg, même ceux qui
avaient une sténose mitrale modérée (SM ≥ 1.5 cm²). Par conséquent, à
l’écho-doppler de stress, le gradient mitral moyen au pic de l’effort justifiant
la dilatation mitrale est probablement supérieur à 15 mm Hg.
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Aims: To assess the safety, efficacy, and long term results of percutaneous
mitral balloon commisurotomy (PMC) for rheumatic mitral stenosis in chil-
dren and adolescents in comparison to adults.
Methods: The results of 361 patients with mitral stenosis who underwent
successful PMC and were followed up for 5 years were analysed. Patients
were divided according to age at the time of PMC into group 1 consisting of
66 patients (=<18 years of age (children and adolescents) and group 2 that
included 295 patients (age> 18 (adults)).
Results: Patients in group 1 had a smaller Doppler mitral valve area
(MVA) (0.76 (+/-0.17) vs 0.87 (+/-0.18) cm2, p, 0.002), and higher Doppler
mitral valve gradient (13.7 (+/-3.3) vs 11.1 (+/-2.5) mm Hg, p, 0.001) than
group 2. Immediately after PMC group 1 had larger MVA measured by Dop-
pler (2.05 (+/-0.30) vs 1.88 (+/-0.22) cm2, p, 0.05) and similar complication
rates, compared to group 2. After a mean follow up of 5 (+/-3.5) years there
was no significant difference between groups 1 and 2 in the incidence of res-
tenosis (11.6% vs 13.4%, NS). Event-free survival rates at 5 and10 years were
92% and 84% for group 1 and 94% and 89% for group 2 (p=0.26).
Conclusions: PMC is safe and effective in children and adolescents with
rheumatic mitral stenosis. It provides better immediate results than in adults
and excellent long term results that are comparable to those seen in adults.
